603229 奥翔药业
已收盘 02-10 15:00:00
资讯
新帖
简况
奥翔药业公布国际专利申请：“一种角鲨胺关键中间体的制备方法”
证券之星 · 02-07
奥翔药业公布国际专利申请：“一种角鲨胺关键中间体的制备方法”
奥翔药业(603229.SH)合作产品枸橼酸托法替布片获得境外上市许可
智通财经 · 02-05
奥翔药业(603229.SH)合作产品枸橼酸托法替布片获得境外上市许可
每周股票复盘：奥翔药业（603229）完成5000万元股份回购
证券之星 · 01-25
每周股票复盘：奥翔药业（603229）完成5000万元股份回购
奥翔药业（603229）披露股份回购实施结果暨股份变动的公告，1月23日股价下跌0.2%
证券之星 · 01-23
奥翔药业（603229）披露股份回购实施结果暨股份变动的公告，1月23日股价下跌0.2%
每周股票复盘：奥翔药业（603229）已回购520万股耗资5000万
证券之星 · 01-11
每周股票复盘：奥翔药业（603229）已回购520万股耗资5000万
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，1月5日股价上涨1.92%
证券之星 · 01-05
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，1月5日股价上涨1.92%
每周股票复盘：奥翔药业（603229）获两项原料药上市批准
证券之星 · 01-02
每周股票复盘：奥翔药业（603229）获两项原料药上市批准
奥翔药业（603229）披露获得化学原料药上市申请批准通知书，12月30日股价下跌0.53%
证券之星 · 2025-12-30
奥翔药业（603229）披露获得化学原料药上市申请批准通知书，12月30日股价下跌0.53%
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%
证券之星 · 2025-12-01
奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%
每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员
证券之星 · 2025-11-23
每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员
奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%
证券之星 · 2025-11-18
奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%
奥翔药业：选举职工代表董事
证券日报网 · 2025-11-18
奥翔药业：选举职工代表董事
每周股票复盘：奥翔药业（603229）拟取消监事会
证券之星 · 2025-11-09
每周股票复盘：奥翔药业（603229）拟取消监事会
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%
证券之星 · 2025-11-04
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%
奥翔药业：10月份公司未实施股份回购
证券日报网 · 2025-11-03
奥翔药业：10月份公司未实施股份回购
每周股票复盘：奥翔药业（603229）Q3净利降23.33%
证券之星 · 2025-11-02
每周股票复盘：奥翔药业（603229）Q3净利降23.33%
奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”
证券之星 · 2025-11-01
奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”
图解奥翔药业三季报：第三季度单季净利润同比下降23.33%
证券之星 · 2025-10-30
图解奥翔药业三季报：第三季度单季净利润同比下降23.33%
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%
证券之星 · 2025-10-30
奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%
每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元
证券之星 · 2025-10-12
每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元
加载更多
公司概况
公司名称：
浙江奥翔药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-05-09
主营业务：
浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药、医药中间体。
发行价格：
7.81
{"stockData":{"symbol":"603229","market":"SH","secType":"STK","nameCN":"奥翔药业","latestPrice":9.87,"timestamp":1770706800000,"preClose":9.85,"halted":0,"volume":4849292,"delay":0,"changeRate":0.002,"floatShares":830000000,"shares":830000000,"eps":0.2227,"marketStatus":"已收盘","change":0.02,"latestTime":"02-10 15:00:00","open":9.83,"high":9.95,"low":9.8,"amount":47954400,"amplitude":0.0152,"askPrice":9.88,"askSize":17,"bidPrice":9.87,"bidSize":797,"shortable":0,"etf":0,"ttmEps":0.2227,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.85,"symbolType":"stock","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":10.84,"lowLimit":8.87,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":830297145,"isCdr":false,"pbRate":3.49,"roa":"--","peRate":44.319713,"roe":"8.86%","epsLYR":0.25,"committee":0.153936,"marketValue":8195000000,"turnoverRate":0.0058,"status":0,"floatMarketCap":8195000000},"requestUrl":"/m/hq/s/603229","defaultTab":"news","newsList":[{"id":"2609851266","title":"奥翔药业公布国际专利申请：“一种角鲨胺关键中间体的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2609851266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609851266?lang=zh_cn&edition=full","pubTime":"2026-02-07 06:13","pubTimestamp":1770416008,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示奥翔药业（603229）公布了一项国际专利申请，专利名为“一种角鲨胺关键中间体的制备方法”，专利申请号为PCT/CN2025/111693，国际公布日为2026年2月5日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来奥翔药业已公布的国际专利申请2个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了5633.8万元，同比增39.4%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020700003189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2609321823","title":"奥翔药业(603229.SH)合作产品枸橼酸托法替布片获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321823","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321823?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:47","pubTimestamp":1770277675,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥翔药业(603229.SH)发布公告，近日，公司合作伙伴STADAArzneimittel AG(简称“STADA”)的子公司 Spirig HealthCare AG 收到瑞士药品管理局核准签发的枸橼酸托法替布片上市许可。枸橼酸托法替布片是全球首个获批的口服 Janus 激酶抑制剂，属于靶向合成改善病情抗风湿药。它通过抑制细胞内 JAK 信号通路，调节免疫反应，主要用于治疗类风湿关节炎、银屑病关节炎及强直性脊柱炎等自身免疫性疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"奥翔药业(603229.SH)合作产品枸橼酸托法替布片获得境外上市许可","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2606234227","title":"每周股票复盘：奥翔药业（603229）完成5000万元股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234227?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:00","pubTimestamp":1769277639,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，奥翔药业报收于9.85元，较上周的10.02元下跌1.7%。本周，奥翔药业1月19日盘中最高价报10.06元。奥翔药业当前最新总市值81.78亿元，在化学制药板块市值排名74/150，在两市A股市值排名2482/5182。本周关注点公司公告汇总：奥翔药业完成50,006,023.36元股份回购，回购股份5,201,200股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2605405719","title":"奥翔药业（603229）披露股份回购实施结果暨股份变动的公告，1月23日股价下跌0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605405719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605405719?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:27","pubTimestamp":1769178439,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，奥翔药业报收于9.85元，较前一交易日下跌0.2%，最新总市值为81.78亿元。该股当日开盘9.89元，最高9.96元，最低9.82元，成交额达9869.84万元，换手率为1.21%。近日，奥翔药业发布关于股份回购实施结果暨股份变动的公告。公告显示，浙江奥翔药业股份有限公司于2025年1月24日至2026年1月23日期间，通过集中竞价交易方式累计回购股份5,201,200股，占公司总股本的0.63%，回购金额为50,006,023.36元，回购价格区间为7.52元/股至11.39元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2602153555","title":"每周股票复盘：奥翔药业（603229）已回购520万股耗资5000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2602153555","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602153555?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:37","pubTimestamp":1768070228,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，奥翔药业报收于10.26元，较上周的9.92元上涨3.43%。本周，奥翔药业1月7日盘中最高价报10.43元。本周关注点公司公告汇总：奥翔药业已累计回购5,201,200股，支付总金额50,006,023.36元。公司公告汇总奥翔药业关于以集中竞价交易方式回购公司股份的进展公告浙江奥翔药业股份有限公司于2025年1月24日召开董事会，审议通过回购股份方案，拟用于股权激励和/或员工持股计划。2025年12月未实施回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2601007480","title":"奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，1月5日股价上涨1.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601007480","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601007480?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:33","pubTimestamp":1767609217,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，奥翔药业报收于10.11元，较前一交易日上涨1.92%，最新总市值为83.94亿元。该股当日开盘10.07元，最高10.31元，最低10.05元，成交额达1.31亿元，换手率为1.56%。公司近日发布关于以集中竞价交易方式回购公司股份的进展公告。浙江奥翔药业股份有限公司于2025年1月24日召开董事会，审议通过回购股份方案，拟用于股权激励和/或员工持股计划。2025年12月未实施回购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500029235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2600203596","title":"每周股票复盘：奥翔药业（603229）获两项原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2600203596","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600203596?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:46","pubTimestamp":1767289572,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，奥翔药业报收于9.62元，较上周的9.61元上涨0.1%。本周，奥翔药业12月26日盘中最高价报9.69元。本周关注点公司公告汇总：奥翔药业获得哌柏西利和达格列净原料药上市批准。公司公告汇总奥翔药业关于获得化学原料药上市申请批准通知书的公告浙江奥翔药业股份有限公司近日收到国家药品监督管理局核准签发的哌柏西利原料药和达格列净原料药《化学原料药上市申请批准通知书》，批准上述原料药生产上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2595184037","title":"奥翔药业（603229）披露获得化学原料药上市申请批准通知书，12月30日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595184037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595184037?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:28","pubTimestamp":1767104899,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，奥翔药业报收于9.43元，较前一交易日下跌0.53%，最新总市值为78.3亿元。该股当日开盘9.42元，最高9.49元，最低9.39元，成交额达2983.75万元，换手率为0.38%。公司近日发布公告称，浙江奥翔药业股份有限公司近日收到国家药品监督管理局核准签发的哌柏西利原料药和达格列净原料药《化学原料药上市申请批准通知书》，批准上述原料药生产上市。公司对哌柏西利累计研发投入1766万元，对达格列净投入650万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2588700725","title":"奥翔药业（603229）披露以集中竞价交易方式回购公司股份的进展公告，12月01日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588700725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588700725?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:55","pubTimestamp":1764582929,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，奥翔药业报收于9.9元，较前一交易日上涨0.41%，最新总市值为82.2亿元。该股当日开盘9.92元，最高9.96元，最低9.85元，成交额达3563.5万元，换手率为0.43%。公司近日发布关于以集中竞价交易方式回购公司股份的进展公告。公告显示，浙江奥翔药业股份有限公司于2025年1月24日召开董事会，审议通过回购股份方案，拟用于股权激励和/或员工持股计划。2025年11月未实施回购。回购进展符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2585106805","title":"每周股票复盘：奥翔药业（603229）取消监事会并调整董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106805?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:24","pubTimestamp":1763843054,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，奥翔药业报收于9.67元，较上周的10.55元下跌8.34%。本周关注点公司公告汇总：奥翔药业取消监事会，修订公司章程及相关内部制度。公司公告汇总奥翔药业第四届董事会第十次会议于2025年11月18日召开，审议通过《关于确认董事会审计委员会成员和召集人的议案》。刘瑜原为非职工代表董事，变更后董事会仍为9名成员，职工代表董事及兼任高管的董事人数未超过半数。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2584510956","title":"奥翔药业（603229）披露取消监事会并修订公司章程议案获通过，11月18日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584510956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584510956?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:42","pubTimestamp":1763476945,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，奥翔药业报收于10.29元，较前一交易日下跌0.77%，最新总市值为85.44亿元。该股当日开盘10.33元，最高10.43元，最低10.23元，成交额达7276.43万元，换手率为0.85%。近日，奥翔药业发布2025年第一次临时股东大会决议公告，公司于2025年11月18日召开2025年第一次临时股东大会，出席会议的股东所持表决权股份占公司总股本的54.7441%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800040262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2584276953","title":"奥翔药业：选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2584276953","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584276953?lang=zh_cn&edition=full","pubTime":"2025-11-18 21:42","pubTimestamp":1763473320,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月18日晚间，奥翔药业发布公告称，公司于2025年11月18日在公司新办公楼一楼会议室召开职工代表大会，选举刘瑜先生担任公司第四届董事会职工代表董事。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-18/doc-infxvtuw3896357.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-18/doc-infxvtuw3896357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2582864919","title":"每周股票复盘：奥翔药业（603229）拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864919","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582864919?lang=zh_cn&edition=full","pubTime":"2025-11-09 05:05","pubTimestamp":1762635920,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，奥翔药业报收于10.08元，较上周的10.25元下跌1.66%。本周，奥翔药业11月6日盘中最高价报10.5元。奥翔药业当前最新总市值83.69亿元，在化学制药板块市值排名68/151，在两市A股市值排名2211/5166。公司拟取消监事会，其职权由董事会审计委员会行使，现任监事将解任。会议采取现场与网络投票相结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2580753991","title":"奥翔药业（603229）披露拟取消监事会并修订公司章程议案，11月04日股价下跌2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580753991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580753991?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:43","pubTimestamp":1762267403,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，奥翔药业报收于10.02元，较前一交易日下跌2.34%，最新总市值为83.2亿元。该股当日开盘10.2元，最高10.29元，最低9.93元，成交额达9393.98万元，换手率为1.13%。公司近日发布公告称，将于2025年11月18日召开2025年第一次临时股东大会，审议《关于取消监事会并修订〈公司章程〉的议案》和《关于修订公司部分内部管理制度的议案》。公告显示，奥翔药业拟取消监事会，其原有职权由董事会审计委员会行使，现任监事将予以解任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603229"],"gpt_icon":0},{"id":"2580496214","title":"奥翔药业：10月份公司未实施股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2580496214","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580496214?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:38","pubTimestamp":1762177080,"startTime":"0","endTime":"0","summary":"证券日报网讯11月3日晚间，奥翔药业发布公告称，2025年10月，公司未实施股份回购。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcvcm0806235.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-03/doc-infwcvcm0806235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2580787408","title":"每周股票复盘：奥翔药业（603229）Q3净利降23.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580787408","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580787408?lang=zh_cn&edition=full","pubTime":"2025-11-02 09:12","pubTimestamp":1762045932,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥翔药业报收于10.25元，较上周的10.14元上涨1.08%。本周，奥翔药业10月31日盘中最高价报10.28元。股本股东变化截至2025年9月30日，奥翔药业股东户数为3.2万户，较6月30日增加1708户，增幅5.64%。业绩披露要点奥翔药业2025年三季报显示，前三季度主营收入6.46亿元，同比下降6.4%；归母净利润2.07亿元，同比下降9.59%；扣非净利润1.83亿元，同比下降13.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2580692414","title":"奥翔药业公布国际专利申请：“卢美哌隆中间体及其制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580692414","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580692414?lang=zh_cn&edition=full","pubTime":"2025-11-01 05:49","pubTimestamp":1761947386,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示奥翔药业（603229）公布了一项国际专利申请，专利名为“卢美哌隆中间体及其制备方法”，专利申请号为PCT/CN2025/090864，国际公布日为2025年10月30日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来奥翔药业已公布的国际专利申请2个，较去年同期减少了33.33%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了5633.8万元，同比增39.4%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100004820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2579148279","title":"图解奥翔药业三季报：第三季度单季净利润同比下降23.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579148279","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579148279?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:25","pubTimestamp":1761823555,"startTime":"0","endTime":"0","summary":"证券之星消息，奥翔药业2025年三季报显示，前三季度公司主营收入6.46亿元，同比下降6.4%；归母净利润2.07亿元，同比下降9.59%；扣非净利润1.83亿元，同比下降13.83%；其中2025年第三季度，公司单季度主营收入1.64亿元，同比下降17.01%；单季度归母净利润3768.58万元，同比下降23.33%；单季度扣非净利润3210.87万元，同比下降20.42%；负债率23.3%，投资收益1924.35万元，财务费用-429.16万元，毛利率56.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000039916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229"],"gpt_icon":0},{"id":"2579115149","title":"奥翔药业（603229）披露拟取消监事会并修订公司章程议案，10月30日股价下跌1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579115149","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579115149?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:58","pubTimestamp":1761818313,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，奥翔药业报收于9.99元，较前一交易日下跌1.48%，最新总市值为82.95亿元。近日，奥翔药业发布关于召开2025年第一次临时股东大会的通知。审议事项包括关于取消监事会并修订《公司章程》的议案，以及修订《股东会议事规则》《董事会议事规则》《独立董事工作制度》等多项内部管理制度的议案。其中，取消监事会并修订《公司章程》为特别决议议案，对中小投资者单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000035353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0},{"id":"2574146339","title":"每周股票复盘：奥翔药业（603229）累计回购520万股耗资5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574146339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574146339?lang=zh_cn&edition=full","pubTime":"2025-10-12 03:45","pubTimestamp":1760211914,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，奥翔药业报收于10.17元，较上周的10.2元下跌0.29%。本周，奥翔药业10月9日盘中最高价报10.3元。奥翔药业当前最新总市值84.44亿元，在化学制药板块市值排名68/150，在两市A股市值排名2192/5158。截至2025年9月30日，公司累计回购股份5,201,200股，占总股本0.63%，已支付总金额50,006,023.36元，回购最高价为11.39元/股，最低价为7.52元/股。2025年9月未实施回购。上述回购进展符合相关规定，公司将继续根据市场情况推进回购并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603229","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770715609227,"stockEarnings":[{"period":"1week","weight":0.0155},{"period":"1month","weight":-0.04},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.1375},{"period":"1year","weight":0.1262},{"period":"ytd","weight":-0.0071}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江奥翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31998人(较上一季度增加5.64%)","perCapita":"25948股","listingDate":"2017-05-09","address":"浙江省台州市临海市化学原料药基地临海园区东海第四大道5号","registeredCapital":"83029万元","survey":" 浙江奥翔药业股份有限公司的主营业务是制剂、特色原料药及医药中间体的研发、生产与销售，以及为客户提供定制生产和研发业务。公司的主要产品是制剂、特色原料药、医药中间体。","listedPrice":7.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥翔药业,603229,奥翔药业股票,奥翔药业股票老虎,奥翔药业股票老虎国际,奥翔药业行情,奥翔药业股票行情,奥翔药业股价,奥翔药业股市,奥翔药业股票价格,奥翔药业股票交易,奥翔药业股票购买,奥翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥翔药业(603229)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥翔药业(603229)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}